Medicare paid $408 million for ineligible over-the-counter drugs, HHS OIG audit finds
An HHS Office of Inspector General audit found Medicare paid at least $408 million for over-the-counter drugs and other ineligible items from January 2023 through June 2025. The audit examined Medicare Advantage and Part D plan payments. The OIG recommended CMS instruct insurers to strengthen payment controls and recover improper payments. While the audit focuses on plan oversight, it signals broader scrutiny of drug category payments. Billing teams for practices that dispense or prescribe high-volume drug categories should monitor payer bulletins for any new coverage or documentation requirements stemming from this finding.